In this issue:
- Metastatic CRC outcomes in public vs private hospitals
- Neoadjuvant FOLFIRINOX for locally advanced rectal cancer
- Outcomes of patients with CRC in NZ
- Inequitable use of chemotherapy in NZ CRC
- Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer
- Benefits of the Australian CRC screening program
- Celecoxib + standard adjuvant therapy in patients with stage III colon cancer
- Fluoropyrimidine + oxaliplatin in MSI colon cancer
- Pembrolizumab in MSI advanced CRC
- Neoadjuvant short-course radiotherapy for upper third rectal tumors
Please login below to download this issue (PDF)